<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559204</url>
  </required_header>
  <id_info>
    <org_study_id>IIV4-PPV23</org_study_id>
    <nct_id>NCT04559204</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4</brief_title>
  <official_title>A Multi-centered, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Combined Immunization of 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) and Quadrivalent Inactivated Influenza Vaccine (IIV4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fujian Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Institute of Biological Products Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changchun Institute of Biological Products Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be recruited and divided into 3 groups:&#xD;
&#xD;
        1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4;&#xD;
&#xD;
        2. Control Group A (408 subjects): IIV4 only;&#xD;
&#xD;
        3. Control Group B (408 subjects): PPV23 only;&#xD;
&#xD;
      All blood samples will be collected before and one month after vaccinatioin. The&#xD;
      immunogenicity and safety of both experimental and control groups will be compared and the&#xD;
      data be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and immunogenicity of simultaneously immunization of 23-valent&#xD;
      pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine&#xD;
      (IIV4) , we design this randomized, parallel controlled study . 1224 subjects are divided&#xD;
      into 3 groups, including 1 experimental group and 2 control groups (control group A and B),&#xD;
      each group includes 408 subjects respectively.&#xD;
&#xD;
      Each 408-subject group is divided again into 4 age-based subgroups: ① 3-8 years old; ② 9-18&#xD;
      years old; ③ 19-49 years old ; ④ over 50 years old; each subgroup includes 102 subjects&#xD;
      respectively.&#xD;
&#xD;
      408 subjects from experimental group will be simultaneously administrated with one dose of&#xD;
      IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination&#xD;
      and one month (30 days) later.&#xD;
&#xD;
      408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml).&#xD;
      Blood samples are collected before vaccination and one month (30 days) later.&#xD;
&#xD;
      408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml).&#xD;
      Blood samples are collected before vaccination and one month (30 days) later.&#xD;
&#xD;
      To evaluate the immunogenicity, we will detect and compare the neutralization antibody&#xD;
      levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of&#xD;
      all groups will be monitored as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">November 26, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate (IIV4)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (IIV4)</measure>
    <time_frame>Results obtained 1 month after vaccination</time_frame>
    <description>the rate of positive seroconversion against influenza A (H3N2, H1N1) type and B (BY, BV) type viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (PPV23)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>the rate of positive seroconversion against 23 pneumococcal serotypes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate (PPV23)</measure>
    <time_frame>Results obtained 1 month after vaccination</time_frame>
    <description>the rate of positive seroconversion against 23 pneumococcal serotypes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (IIV4)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>GMCs of influenza A (H3N2, H1N1) type and B (BY, BV) type viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (IIV4)</measure>
    <time_frame>Results obtained 1 month after vaccination</time_frame>
    <description>GMCs of influenza A (H3N2, H1N1) type and B (BY, BV) type viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (PPV23)</measure>
    <time_frame>Baseline (before vaccination) results</time_frame>
    <description>GMCs of 23 pneumococcal serotypes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) (PPV23)</measure>
    <time_frame>Results obtained 1 month after vaccination</time_frame>
    <description>GMCs of 23 pneumococcal serotypes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events following vaccination</measure>
    <time_frame>0-1 month (30 days)</time_frame>
    <description>analyse the incidence of adverse events following immunization, both solicited and unsolicited</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1224</enrollment>
  <condition>Influenza, Human</condition>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IIV4 and PPV23</intervention_name>
    <description>imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IIV4</intervention_name>
    <description>administrated with IIV4 only</description>
    <arm_group_label>control group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPV23</intervention_name>
    <description>administrated with PPV23 only</description>
    <arm_group_label>control group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects aged no younger than 3 years old on the day of recruitment;&#xD;
&#xD;
          -  with valid informed consent signed by parent(s) or guardian(s);&#xD;
&#xD;
          -  parent(s) or guardian(s) are able to attend all scheduled appointments and comply with&#xD;
             all study instructions;&#xD;
&#xD;
          -  subjects have not received any seasonal influenza vaccine or pneumonia vaccine before;&#xD;
&#xD;
          -  axillary temperature ≤37.0℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject who has a medical history with hypersensitiveness, eclampsia, epilepsy,&#xD;
             cerebropathia or neurological illness;&#xD;
&#xD;
          -  allergic to any ingredient of vaccine or with allergy history to any vaccine;&#xD;
&#xD;
          -  subjects with immunodeficency or suspected impairment of immunologic function (e.g.&#xD;
             caused by HIV), or subjects are in the process of immunosuppressor therapy(taking&#xD;
             orally injecting of steroid hormone);&#xD;
&#xD;
          -  administration of immunoglobulins within 30 days prior to this study;&#xD;
&#xD;
          -  acute febrile disease(temperature ≥ 37.0°C) or infectious disease;&#xD;
&#xD;
          -  have a clearly diagnosed history of thrombocytopenia or other coagulopathy, which&#xD;
             might cause contraindications for subcutaneous injection;&#xD;
&#xD;
          -  any serious chronic illness, acute infectious diseases, or respiratory diseases;&#xD;
             severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with&#xD;
             complications;&#xD;
&#xD;
          -  any kind of infectious, purulent, or allergic skin diseases;&#xD;
&#xD;
          -  pregnant women and breastfeeding women;&#xD;
&#xD;
          -  inoculated with any vaccine within 14 days of the study;&#xD;
&#xD;
          -  any other factor that makes the investigator determines the subject is unsuitable for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanying Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liucheng Community Health Services Center</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luodong County Health Center</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingzhen Center for Disease Control and Prevention</name>
      <address>
        <city>Qingzhen</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qidong County Center for Disease Control and Prevention</name>
      <address>
        <city>Qidong</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>23-valent Pneumococcal Polysaccharide Vaccine</keyword>
  <keyword>Quadrivalent Inactivated Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

